补肾复方冲剂影响再生障碍性贫血患者造血祖细胞研究

在探讨补肾复方冲剂治疗肾阳虚型再生障碍性贫血 (简称再障 )临床疗效基础上 ,观察其对于再障患者骨髓造血祖细胞影响。以补肾复方冲剂治疗 30例 ,复方皂矾丸、康力龙各治疗 15例。采用甲基纤维素培养法观察 3组病例治疗前、后骨髓造血祖细胞水平变化 ,并与正常献血员对照。结果示补肾复方组临床有效率为 80 % ,明显高于复方皂矾丸 ( 4 0 % )与康力龙组 ( 4 6 67% ) ;且补肾复方组治疗有效病例的骨髓造血祖细胞 (BFU E及CFU GM )恢复明显优于复方皂矾丸与康力龙组 ;3组间无效者骨髓BFU E及CFU GM水平无明显变化。说明补肾复方冲剂治疗肾阳虚型再障疗效不仅高于复方皂矾丸和康力龙组 ,且其有效者血液学恢复更为完全。

Study of the Effects of Bushen Compound Instant Granules on the Hematopoietic Progenitor Cells in the Patients with Aplastic Anemia

The study was to observe the effects of Bushen Compound Instant Granules (BCIG) on the bone marrow hematopoietic progenitor cells (BMHPC) in the patients with aplastic anemia of the kidney yang deficiency type. 30 Cases were treated with BCIG, 15 cases with Compound Zaofan Pills (CZP), and 15 cases with stanozolol; the changes in the levels of BMHPC in the 3 groups were observed before and after the treatment by the methyl cellulose culture method, with a control group consisting of 15 healthy human subjects. The results showed that the clinical effective rate of the BCIG group was 80%, obviously higher than those of the CZP group (40%) and stanozolol group (46.67%); the recovery of the levels of bone marrow BFU E and CFU GM in the effective cases in the BCIG group was more obvious than that in the effective cases in the CZP group and stanozolol group; and there were no obvious changes in the levels of bone marrow BFU E and CFU GM in the ineffective cases in all the 3 groups. It could be seen from the results that the effective rate of BCIG in treating aplastic anemia of the kidney yang deficiency type was higher than those of CZP and stanozolol, and the hematological recovery of the patients responding to BCIG was more complete.